Posts by Meghan E. Sise, MD
-
Acute Kidney Injury Possible with Tisagenlecleucel CAR T Therapy
Massachusetts General Hospital researchers observed low rates of acute kidney injury (AKI) after tisagenlecleucel therapy but detected the first case of AKI in a patient with macrophage activation syndrome/hemophagocytic lymphohistiocytosis triggered by the therapy.
-
Pharmacologic Treatment of COVID-19: What Nephrologists Need to Know
Massachusetts General Hospital clinicians report that nephrology consults are warranted when nucleotide analogs are used to treat COVID-19.
-
Medical Grand Rounds: COVID-19 and Acute Kidney Injury
On May 21, 2020, the eleventh lecture in the Medical Grand Rounds’ COVID-19 series featured a panel of experts who are investigating kidney disease and COVID-19.
Biography
Meghan Sise, MD, is a nephrologist in the Department of Medicine at Massachusetts General Hospital. Her research is focused on determining the impact and mechanism of Hepatitis C Virus (HCV) on the progression of chronic kidney disease (CKD) through clinical and translational investigation in patients with HCV mono-infection and co-infection with HCV and human immunodeficiency virus (HIV). Sise has focused on the safety and efficacy of novel direct-acting antiviral agents for HCV in both patients with chronic kidney disease and end-stage renal disease on dialysis. She conducts clinical trials and longitudinal observational studies in these populations. Meghan Sise currently holds a faculty appointment at Massachusetts General Hospital in the Division of Nephrology with 75% of her time dedicated to research and she maintains an active clinical presence with 20% clinical and 5% teaching effort.
